Screener / SEC EDGAR /CIK 0001609550 /10-K filed Feb 13, 2026, compared with Feb 10, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
NYSE Health care · Medical Instruments

Inspire Medical Systems, Inc. INSP

We are a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea ("OSA"). 10-K, Item 1

Employees
1,333
Headquarters
Golden Valley, MN
CEO
Timothy P. Herbert
Next results
around Jan 11, 2027
Compare with peers Embed

Where each dollar of revenue went, FY2025

Revenue of $912.0M through the costs to a net profit of $145.4M · income statement of the 10-K

6% operating margin
Revenue to Gross profit: $778.8MRevenue to Cost of revenue: $133.2MGross profit to Operating profit: $51.0MGross profit to Operating expenses: $727.8MOperating profit to Net profit: $51.0MOther income to Net profit: $94.5MOperating expenses to R&D: $103.2MOperating expenses to SG&A: $624.6M Revenue: $912.0M REVENUE $912.0M +14% Y/Y Gross profit: $778.8M · 85% margin GROSS PROFIT $778.8M 85% margin · +15% Y/Y Cost of revenue: $133.2M · 15% of revenue COST OF REVENUE $133.2M 15% of revenue Operating profit: $51.0M · 6% margin OPERATING PROFIT $51.0M 6% margin · +41% Y/Y Other income: $94.5M · 10% of revenue OTHER INCOME $94.5M 10% of revenue Operating expenses: $727.8M · 80% of revenue OPERATING EXPENSES $727.8M 80% of revenue Net profit: $145.4M · 16% margin NET PROFIT $145.4M 16% margin · +172% Y/Y R&D: $103.2M · 11% of revenue R&D $103.2M 11% of revenue SG&A: $624.6M · 68% of revenue SG&A $624.6M 68% of revenue
Gross profit $778.8M 85% margin · +15% Y/Y
Operating profit $51.0M 6% margin · +41% Y/Y
Net profit $145.4M 16% margin · +172% Y/Y
The full income statement, year by year

INSP among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: 13.6%, above 62% of 154 peers (their median 10.4%) REVENUE GROWTH 13.6% · above 62% Gross margin: 86.2%, above 90% of 107 peers (their median 63.4%) GROSS MARGIN 86.2% · above 90% Operating margin: 1.8%, above 31% of 138 peers (their median 10.2%) OPERATING MARGIN 1.8% · above 31% Net margin: 11.4%, above 63% of 153 peers (their median 6.7%) NET MARGIN 11.4% · above 63% FCF margin: 11.1%, above 55% of 144 peers (their median 9.9%) FCF MARGIN 11.1% · above 55% Return on capital: 13.6%, above 80% of 89 peers (their median 9.0%) RETURN ON CAPITAL 13.6% · above 80%
INSP Peer median Below the median

What changed

29 new risk paragraphs and 3 accounting facts worth reading about. 10-K filed Feb 13, 2026 against Feb 10, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

3facts worth reading about the other 8 checks found nothing to note

  • Receivables growing faster than revenue
    Receivables +28.6% ($93.1M to $119.7M) vs revenue +13.6% ($802.8M to $912.0M), +15.0 pts apart
  • Cash from operations lower than net income
    Cash from operations $117.0M vs net income $145.4M (FY ending Dec 31, 2025)
  • Inventory growing faster than revenue
    Inventory +81.3% ($80.1M to $145.3M) vs revenue +13.6% ($802.8M to $912.0M), +67.7 pts apart
  • Same auditor in both 10-Ks: Ernst & Young LLP
7 more checks with nothing to note
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • The same matters as last year: Reserves for excess and obsolete inventory
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

29 paragraphs in Risk Factors that were not in the 10-K filed Feb 10, 2025. Quoted as filed.

All 29 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 10, 2025 10-K, ITEM 1A
    Additionally, securities class action litigations are often brought against companies following periods of volatility in the overall market and in the market price of a company’s securities. We have experienced these in the past, have such cases pending now and may have such cases in the future. On November 6, 2025, the City of Pontiac…
  2. Item 1A · new paragraph · not in the 10-K filed Feb 10, 2025 10-K, ITEM 1A
    In addition, we are currently a party to multiple adversarial proceedings with Nyxoah regarding our patent portfolio and the patents of third parties. For additional information, see Note 11, Commitments and Contingencies to the
  3. Item 1A · new paragraph · not in the 10-K filed Feb 10, 2025 10-K, ITEM 1A
    In the course of conducting our business, we must adequately address quality issues that may arise with our Inspire system, including defects in third-party components included in our Inspire system. There can be no
  4. Item 1A · new paragraph · not in the 10-K filed Feb 10, 2025 10-K, ITEM 1A
    We rely extensively on information technology systems to conduct our business and collect, store, process and transmit confidential and sensitive information, including personal information of (or relating to) customers, patients and our employees and contractors. These systems support, among other things, manufacturing and…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$407.9M$624.8M$802.8M$912.0M
Net income−$44.9M−$21.2M$53.5M$145.4M
Operating cash flow$11.6M$24.7M$130.2M$117.0M
Free cash flow$2.5M$1.0M$91.1M$78.5M

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$912.0M ▲ 13.6% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

2 filings in the last 30 days · SEC EDGAR

All filings

About the company

Inspire Medical Systems, Inc., Golden Valley, MN · from the 10-K filed Feb 13, 2026

We are a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea ("OSA"). Our proprietary Inspire system is the first FDA, European Union ("EU") Regulation No. 2017/745 ("MDR" or "EU Medical Devices Regulation"), and Japan Pharmaceuticals and Medical Devices Agency-approved neurostimulation technology of its kind that provides a safe and effective treatment for patients with moderate to severe OSA. We have developed a novel, closed-loop solution that continuously monitors a patient’s breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway.

Headquarters
Golden Valley, MN
Country
United States
Reports in
USD
Listed on
NYSE
Fiscal year ends
December 31
Last results
Nov 2, 2026
Incorporated in
DE

Employees, at the top of the page: "As of December 31, 2025, we had 1,333 employees, of which 1,243 are in the U" (10-K). Address and exchange: SEC's company file.

Email alerts

Sources

The 10-K filed Feb 13, 2026 (open at SEC), compared with the 10-K filed Feb 10, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/INSP/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.